These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11868688)

  • 1. Activated protein C in severe sepsis.
    Bradley C
    Intensive Crit Care Nurs; 2001 Jun; 17(3):177-8. PubMed ID: 11868688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe sepsis.
    Bernard G
    Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
    Dhainaut JF
    Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
    [No Abstract]   [Full Text] [Related]  

  • 4. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
    Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 6. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
    Doig CJ; Laupland KB; Zygun DA; Manns BJ
    Expert Opin Pharmacother; 2003 Oct; 4(10):1789-99. PubMed ID: 14521488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 8. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
    Morris PE; Light RB; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
    Pastores SM
    Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 14. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
    Durthaler JM; Ernst FR
    Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
    [No Abstract]   [Full Text] [Related]  

  • 17. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
    Haas I
    Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
    [No Abstract]   [Full Text] [Related]  

  • 18. The last Xigris® survivor.
    Barie PS
    Surg Infect (Larchmt); 2011 Dec; 12(6):423-5. PubMed ID: 22185189
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
    Kanji S; Perreault MM; Chant C; Williamson D; Burry L
    Intensive Care Med; 2007 Mar; 33(3):517-23. PubMed ID: 17325837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we treat severe sepsis with activated protein C?
    Mackillop A
    Hosp Med; 2003 May; 64(5):316. PubMed ID: 12789748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.